MedTrace Logo

National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin

NCT00097539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65205

Last updated 2017-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this multicenter, open-label, observational, post-marketing surveillance study is to collect long term safety and efficacy information on growth hormone (GH) products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) in the treatment of pediatric growth disorders for which GH is prescribed.

Conditions

  • Growth Disorders

Interventions

BIOLOGICAL

Somatrem

BIOLOGICAL

Somatropin

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1985-10-31
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097539 on ClinicalTrials.gov